carbocisteine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
mucolytics	4160	638-23-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: carbocisteine bronchokod carbocit carbocysteine chilvax L-(Carboxymethyl)cysteine lisil lisomucil loviscol muciclar mucocis mucodyne mucofan mucolase mucolex mucopront mucosol mucotab mukinyl PectDrill pectox pulmoclase reomucil rhinathiol rhinatiol thiodril transbronchin carbocisteine sodium	A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action. Molecular weight: 179.19 Formula: C5H9NO4S CLOGP: -2.61 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 100.62 ALOGS: -0.92 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

carbocisteine
bronchokod
carbocit
carbocysteine
chilvax
L-(Carboxymethyl)cysteine
lisil
lisomucil
loviscol
muciclar
mucocis
mucodyne
mucofan
mucolase
mucolex
mucopront
mucosol
mucotab
mukinyl
PectDrill
pectox
pulmoclase
reomucil
rhinathiol
rhinatiol
thiodril
transbronchin
carbocisteine sodium

A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action.

Molecular weight: 179.19
Formula: C5H9NO4S
CLOGP: -2.61
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 100.62
ALOGS: -0.92
ROTB: 5

Drug dosage:

Dose	Unit	Route
1.50	g	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary pain	106.20	18.47	32	7842	3458	63477690
Upper respiratory tract inflammation	80.51	18.47	24	7850	2499	63478649
Hepatic function abnormal	73.97	18.47	50	7824	37092	63444056
Amyloid arthropathy	70.56	18.47	16	7858	564	63480584
Drug ineffective	67.54	18.47	23	7851	1044742	62436406
Interstitial lung disease	63.10	18.47	56	7818	61852	63419296
Drug eruption	55.63	18.47	38	7836	28656	63452492
Lower respiratory tract infection	55.60	18.47	75	7799	132232	63348916
Platelet count decreased	53.70	18.47	69	7805	116053	63365095
Adrenal suppression	53.40	18.47	14	7860	910	63480238

Showing 1 to 10 of 46 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	152.40	16.96	126	8314	65156	34883335
Hepatic function abnormal	102.11	16.96	85	8355	44278	34904213
Pneumonia aspiration	85.61	16.96	75	8365	41828	34906663
Pneumonia	81.90	16.96	231	8209	362396	34586095
Lower respiratory tract infection	79.87	16.96	64	8376	31573	34916918
Radiation inflammation	70.58	16.96	20	8420	885	34947606
Pulmonary pain	64.61	16.96	20	8420	1204	34947287
Idiopathic pulmonary fibrosis	47.15	16.96	21	8419	3513	34944978
Lung neoplasm malignant	41.36	16.96	34	8406	17361	34931130
Drug ineffective	39.05	16.96	32	8408	456719	34491772

Showing 1 to 10 of 37 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	199.58	15.57	174	16355	112426	79615433
Hepatic function abnormal	171.47	15.57	133	16396	72974	79654885
Pulmonary pain	158.41	15.57	52	16477	4421	79723438
Pneumonia	118.82	15.57	352	16177	659894	79067965
Upper respiratory tract inflammation	111.73	15.57	39	16490	3996	79723863
Pneumonia aspiration	105.68	15.57	97	16432	66870	79660989
Drug ineffective	95.54	15.57	53	16476	1080860	78646999
Lower respiratory tract infection	85.51	15.57	119	16410	129101	79598758
Pneumonia bacterial	77.76	15.57	49	16480	19282	79708577
Drug eruption	73.93	15.57	66	16463	43869	79683990

Showing 1 to 10 of 100 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	R05CB03	RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS Mucolytics
CHEBI has role	CHEBI:77034	mucolytics
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000891	Anti-Infective Agents, Local
MeSH PA	D005100	Expectorants
MeSH PA	D019141	Respiratory System Agents

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Gastrointestinal ulcer	contraindication	40845000
Gastrointestinal hemorrhage	contraindication	74474003

Showing 1 to 2 of 2 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.15	acidic
pKa2	2.79	acidic
pKa3	9.51	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
003677	NDDF
193653	PUBCHEM_CID
2023	RXNORM
26469	MMSL
2884	INN_ID
395842001	SNOMEDCT_US
740J2QX53R	UNII
772923009	SNOMEDCT_US
C0006992	UMLSCUI
CAY	PDB_CHEM_ID

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

None